PDF herunterladen
CC BY-NC-ND 4.0 · Rev Bras Ginecol Obstet 2017; 39(12): 676-685
DOI: 10.1055/s-0037-1608867
Review Article
Thieme Revinter Publicações Ltda Rio de Janeiro, Brazil

Is Ovarian Cancer Prevention Currently Still a recommendation of Our Grandparents?

A prevenção do câncer de ovário ainda é uma recomendação de nossos avós?
Millena Prata Jammal
1   Research Institute of Oncology (IPON), Discipline of Gynecology and Obstetrics; Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil
,
Cid Almeida de Lima
1   Research Institute of Oncology (IPON), Discipline of Gynecology and Obstetrics; Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil
,
Eddie Fernando Candido Murta
1   Research Institute of Oncology (IPON), Discipline of Gynecology and Obstetrics; Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil
,
Rosekeila Simões Nomelini
1   Research Institute of Oncology (IPON), Discipline of Gynecology and Obstetrics; Universidade Federal do Triângulo Mineiro, Uberaba, MG, Brazil
› Institutsangaben
Weitere Informationen

Publikationsverlauf

24. Juni 2017

17. Oktober 2017

Publikationsdatum:
27. November 2017 (online)

   Lizenzen und Reprints

Abstract

Ovarian cancer is the leading cause of death among gynecologic tumors because in most of the cases (75%), the disease is diagnosed in advanced stages. Screening methods are not available since the disease is rare, and the tested methods, such as ultrasound and CA125, were not able to decrease the mortality rate for this type of cancer. This article discusses the main risk factors for ovarian cancer, and the potential clinical and surgical strategies for the prevention of this disease.

Resumo

O câncer de ovário é a principal causa de morte entre os tumores ginecológicos, já que na maioria dos casos (75%) o diagnóstico ocorre em estádios avançados. Métodos de rastreamento não estão disponíveis, já que a doença é rara, e os métodos diagnósticos, como ultrassonografia e CA 125, não são capazes de reduzir a taxa de mortalidade desse câncer. Este artigo discute os principais fatores de risco para o câncer de ovário e as possíveis estratégias clínicas e cirúrgicas para a prevenção dessa doença.

Keywords

ovarian neoplasms - primary prevention - oophorectomy - salpingectomy - lifestyle

Palavras-chave

neoplasias ováricas - prevenção primária - ovariectomia - salpingectomia - estilo de vida
 

  • References

  • 1 Jia L, Ren JM, Wang YY. , et al. Inhibitory role of prohibitin in human ovarian epithelial cancer. Int J Clin Exp Pathol 2014; 7 (05) 2247-2255
    PubMedGoogle Scholar
  • 2 Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010; 60 (05) 277-300
    CrossrefPubMedGoogle Scholar
  • 3 Jelovac D, Armstrong DK. Recent progress in the diagnosis and treatment of ovarian cancer. CA Cancer J Clin 2011; 61 (03) 183-203
    CrossrefPubMedGoogle Scholar
  • 4 American Cancer Society. Cancer Facts & Figures 2017 . Atlanta, GA: ACS; 2017. https://www.cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures/cancer-facts-figures-2017.html . Accessed March 10, 2017
    PubMedGoogle Scholar
  • 5 Gadducci A, Cosio S, Zola P, Landoni F, Maggino T, Sartori E. Surveillance procedures for patients treated for epithelial ovarian cancer: a review of the literature. Int J Gynecol Cancer 2007; 17 (01) 21-31
    CrossrefPubMedGoogle Scholar
  • 6 Tavassoli FA, Devilee P. , Eds. Pathology and Genetics of Tumours of the Breast and Female Genital Organs . Lyon: IARC Press; 2003. . (World Health Organization Classification of Tumours; Vol. 5)
    Google Scholar
  • 7 Feng Y, He F, Wu H. , et al. GOLPH3L is a novel prognostic biomarker for epithelial ovarian cancer. J Cancer 2015; 6 (09) 893-900
    CrossrefPubMedGoogle Scholar
  • 8 Kurman RJ, Shih IeM. The origin and pathogenesis of epithelial ovarian cancer: a proposed unifying theory. Am J Surg Pathol 2010; 34 (03) 433-443
    CrossrefPubMedGoogle Scholar
  • 9 Goff BA, Mandel LS, Drescher CW. , et al. Development of an ovarian cancer symptom index: possibilities for earlier detection. Cancer 2007; 109 (02) 221-227
    CrossrefPubMedGoogle Scholar
  • 10 Wang ZH, Xu CJ. Research progress of microRNA in early detection of ovarian cancer. Chin Med J (Engl) 2015; 128 (24) 3363-3370
    CrossrefPubMedGoogle Scholar
  • 11 Murta EF, Nomelini RS. Early diagnosis and predictors of malignancy of adnexal masses. Curr Opin Obstet Gynecol 2006; 18 (01) 14-19
    CrossrefPubMedGoogle Scholar
  • 12 Partridge E, Kreimer AR, Greenlee RT. , et al; PLCO Project Team. Results from four rounds of ovarian cancer screening in a randomized trial. Obstet Gynecol 2009; 113 (04) 775-782
    CrossrefPubMedGoogle Scholar
  • 13 Claus EB, Schildkraut JM, Thompson WD, Risch NJ. The genetic attributable risk of breast and ovarian cancer. Cancer 1996; 77 (11) 2318-2324
    CrossrefPubMedGoogle Scholar
  • 14 Ciccia A, Elledge SJ. The DNA damage response: making it safe to play with knives. Mol Cell 2010; 40 (02) 179-204
    CrossrefPubMedGoogle Scholar
  • 15 Petrucelli N, Daly MB, Feldman GL. Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genet Med 2010; 12 (05) 245-259
    CrossrefPubMedGoogle Scholar
  • 16 Määttä KM, Nurminen R, Kankuri-Tammilehto M, Kallioniemi A, Laasanen S-L, Schleutker J. Germline EMSY sequence alterations in hereditary breast cancer and ovarian cancer families. BMC Cancer 2017; 17 (01) 496
    CrossrefPubMedGoogle Scholar
  • 17 La Vecchia C. Ovarian cancer: epidemiology and risk factors. Eur J Cancer Prev 2017; 26 (01) 55-62
    CrossrefPubMedGoogle Scholar
  • 18 Hanna L, Adams M. Prevention of ovarian cancer. Best Pract Res Clin Obstet Gynaecol 2006; 20 (02) 339-362
    CrossrefPubMedGoogle Scholar
  • 19 Pylväs-Eerola M, Karihtala P, Puistola U. Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer. BMC Cancer 2015; 15: 493
    CrossrefPubMedGoogle Scholar
  • 20 Clarke-Pearson DL. Clinical practice. Screening for ovarian cancer. N Engl J Med 2009; 361 (02) 170-177
    CrossrefPubMedGoogle Scholar
  • 21 Finch A, Beiner M, Lubinski J. , et al; Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA 2006; 296 (02) 185-192
    CrossrefPubMedGoogle Scholar
  • 22 Rebbeck TR, Lynch HT, Neuhausen SL. , et al; Prevention and Observation of Surgical End Points Study Group. Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. N Engl J Med 2002; 346 (21) 1616-1622
    CrossrefPubMedGoogle Scholar
  • 23 Brawley OW. Ovarian cancer prevention: Time for primetime?. Cancer 2015; 121 (13) 2121-2123
    CrossrefPubMedGoogle Scholar
  • 24 PDQ Screening and Prevention Editorial Board. Ovarian, Fallopian Tube, And Primary Peritoneal Cancer Prevention (PDQ®): Health Professional Version . Jun 2017. https://www.ncbi.nlm.nih.gov/books/NBK65921/ . Accessed July 20, 2017
    PubMedGoogle Scholar
  • 25 Murdoch WJ. Perturbation of sheep ovarian surface epithelial cells by ovulation: evidence for roles of progesterone and poly(ADP-ribose) polymerase in the restoration of DNA integrity. J Endocrinol 1998; 156 (03) 503-508
    CrossrefPubMedGoogle Scholar
  • 26 Modan B, Hartge P, Hirsh-Yechezkel G. , et al; National Israel Ovarian Cancer Study Group. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001; 345 (04) 235-240
    CrossrefPubMedGoogle Scholar
  • 27 Titus-Ernstoff L, Perez K, Cramer DW, Harlow BL, Baron JA, Greenberg ER. Menstrual and reproductive factors in relation to ovarian cancer risk. Br J Cancer 2001; 84 (05) 714-721
    CrossrefPubMedGoogle Scholar
  • 28 Pelucchi C, Galeone C, Talamini R. , et al. Lifetime ovulatory cycles and ovarian cancer risk in 2 Italian case-control studies. Am J Obstet Gynecol 2007; 196 (01) 83.e1-83.e7
    CrossrefPubMedGoogle Scholar
  • 29 Fathalla MF. Incessant ovulation and ovarian cancer - a hypothesis re-visited. Facts Views Vis ObGyn 2013; 5 (04) 292-297
    PubMedGoogle Scholar
  • 30 Havrilesky LJ, Moorman PG, Lowery WJ. , et al. Oral contraceptive pills as primary prevention for ovarian cancer: a systematic review and meta-analysis. Obstet Gynecol 2013; 122 (01) 139-147
    CrossrefPubMedGoogle Scholar
  • 31 Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and body size: individual participant meta-analysis including 25,157 women with ovarian cancer from 47 epidemiological studies. PLoS Med 2012; 9 (04) e1001200
    CrossrefPubMedGoogle Scholar
  • 32 Narod SA, Risch H, Moslehi R. , et al; Hereditary Ovarian Cancer Clinical Study Group. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998; 339 (07) 424-428
    CrossrefPubMedGoogle Scholar
  • 33 Chuffa LG, Lupi-Júnior LA, Costa AB, Amorim JP, Seiva FR. The role of sex hormones and steroid receptors on female reproductive cancers. Steroids 2017; 118: 93-108
    CrossrefPubMedGoogle Scholar
  • 34 Risch HA, Weiss NS, Lyon JL, Daling JR, Liff JM. Events of reproductive life and the incidence of epithelial ovarian cancer. Am J Epidemiol 1983; 117 (02) 128-139
    CrossrefPubMedGoogle Scholar
  • 35 Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, transcription, and cell cycle in response to DNA damage. Cancer Sci 2004; 95 (11) 866-871
    CrossrefPubMedGoogle Scholar
  • 36 Horiuchi A, Itoh K, Shimizu M. , et al. Toward understanding the natural history of ovarian carcinoma development: a clinicopathological approach. Gynecol Oncol 2003; 88 (03) 309-317
    CrossrefPubMedGoogle Scholar
  • 37 Bougie O, Weberpals JI. Clinical Considerations of BRCA1- and BRCA2-mutation carriers: a review. Int J Surg Oncol 2011; 2011: 374012
    PubMedGoogle Scholar
  • 38 van der Kolk DM, de Bock GH, Leegte BK. , et al. Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Res Treat 2010; 124 (03) 643-651
    CrossrefPubMedGoogle Scholar
  • 39 Girolimetti G, Perrone AM, Santini D. , et al. BRCA-associated ovarian cancer: from molecular genetics to risk management. BioMed Res Int 2014; 2014: 787143
    CrossrefPubMedGoogle Scholar
  • 40 Przybycin CG, Kurman RJ, Ronnett BM, Shih IeM, Vang R. Are all pelvic (nonuterine) serous carcinomas of tubal origin?. Am J Surg Pathol 2010; 34 (10) 1407-1416
    CrossrefPubMedGoogle Scholar
  • 41 Kauff ND, Satagopan JM, Robson ME. , et al. Risk-reducing salpingo-oophorectomy in women with a BRCA1 or BRCA2 mutation. N Engl J Med 2002; 346 (21) 1609-1615
    CrossrefPubMedGoogle Scholar
  • 42 Domchek SM, Rebbeck TR. Prophylactic oophorectomy in women at increased cancer risk. Curr Opin Obstet Gynecol 2007; 19 (01) 27-30
    CrossrefPubMedGoogle Scholar
  • 43 Domchek SM, Friebel TM, Neuhausen SL. , et al. Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Lancet Oncol 2006; 7 (03) 223-229
    CrossrefPubMedGoogle Scholar
  • 44 Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecol Oncol 2006; 100 (01) 58-64
    CrossrefPubMedGoogle Scholar
  • 45 Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers?. Am J Obstet Gynecol 2011; 204 (01) 19.e1-19.e6
    CrossrefPubMedGoogle Scholar
  • 46 Society of Gynecologic Oncology. SGO Clinical Practice Statement: Salpingectomy for Ovarian Cancer Prevention . Nov 2013. https://www.sgo.org/clinical-practice/guidelines/sgo-clinical-practice-statement-salpingectomy-for-ovarian-cancer-prevention/ . Accessed January 25, 2017
    PubMedGoogle Scholar
  • 47 Kwon JS, McAlpine JN, Hanley GE. , et al. Costs and benefits of opportunistic salpingectomy as an ovarian cancer prevention strategy. Obstet Gynecol 2015; 125 (02) 338-345
    CrossrefPubMedGoogle Scholar
  • 48 Szender JB, Lele SB. Fallopian tube ligation or salpingectomy as means for reducing risk of ovarian cancer. AMA J Ethics 2015; 17 (09) 843-848
    CrossrefPubMedGoogle Scholar
  • 49 Sieh W, Salvador S, McGuire V. , et al; Australian Cancer Study (Ovarian Cancer); Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium. Tubal ligation and risk of ovarian cancer subtypes: a pooled analysis of case-control studies. Int J Epidemiol 2013; 42 (02) 579-589
    CrossrefPubMedGoogle Scholar
  • 50 Ely LK, Truong M. The role of opportunistic bilateral salpingectomy vs tubal occlusion or ligation for ovarian cancer prophylaxis. J Minim Invasive Gynecol 2017; 24 (03) 371-378
    CrossrefPubMedGoogle Scholar
  • 51 Committee on Gynecologic Practice. Committee opinion no. 620: Salpingectomy for ovarian cancer prevention. Obstet Gynecol 2015; 125 (01) 279-281
    CrossrefPubMedGoogle Scholar
  • 52 Coukos G, Rubin SC. Prophylactic oophorectomy. Best Pract Res Clin Obstet Gynaecol 2002; 16 (04) 597-609
    CrossrefPubMedGoogle Scholar
  • 53 Hanley GE, McAlpine JN, Kwon JS, Mitchell G. Opportunistic salpingectomy for ovarian cancer prevention. Gynecol Oncol Res Pract 2015; 2: 5
    CrossrefPubMedGoogle Scholar
  • 54 Hanley GE, McAlpine JN, Pearce CL, Miller D. The performance and safety of bilateral salpingectomy for ovarian cancer prevention in the United States. Am J Obstet Gynecol 2017; 216 (03) 270.e1-270.e9
    CrossrefPubMedGoogle Scholar
  • 55 Gan C, Chenoy R, Chandrasekaran D. , et al. Persistence of fimbrial tissue on the ovarian surface after salpingectomy. Am J Obstet Gynecol 2017; 217 (04) 425.e1-425.e16
    CrossrefPubMedGoogle Scholar
  • 56 Lum D, Guido R, Rodriguez E. , et al. Brush cytology of the fallopian tube and implications in ovarian cancer screening. J Minim Invasive Gynecol 2014; 21 (05) 851-856
    CrossrefPubMedGoogle Scholar
  • 57 La Vecchia C. Epidemiology of ovarian cancer: a summary review. Eur J Cancer Prev 2001; 10 (02) 125-129
    CrossrefPubMedGoogle Scholar
  • 58 Reid BM, Permuth JB, Sellers TA. Epidemiology of ovarian cancer: a review. Cancer Biol Med 2017; 14 (01) 9-32
    CrossrefPubMedGoogle Scholar
  • 59 Praestegaard C, Jensen A, Jensen SM. , et al; Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium. Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. Int J Cancer 2017; 140 (11) 2422-2435
    CrossrefPubMedGoogle Scholar
  • 60 Seitz HK, Pelucchi C, Bagnardi V, La Vecchia C. Epidemiology and pathophysiology of alcohol and breast cancer: Update 2012. Alcohol Alcohol 2012; 47 (03) 204-212
    CrossrefPubMedGoogle Scholar
  • 61 Chuffa LG, Fioruci-Fontanelli BA, Mendes LO. , et al. Characterization of chemically induced ovarian carcinomas in an ethanol-preferring rat model: influence of long-term melatonin treatment. PLoS One 2013; 8 (12) e81676
    CrossrefPubMedGoogle Scholar
  • 62 Genkinger JM, Hunter DJ, Spiegelman D. , et al. Alcohol intake and ovarian cancer risk: a pooled analysis of 10 cohort studies. Br J Cancer 2006; 94 (05) 757-762
    CrossrefPubMedGoogle Scholar
  • 63 Kim HS, Kim JW, Shouten LJ. , et al. Wine drinking and epithelial ovarian cancer risk: a meta-analysis. J Gynecol Oncol 2010; 21 (02) 112-118
    CrossrefPubMedGoogle Scholar
  • 64 O'Hanlon LH. Studying the connection between exercise and cancer risk reduction. J Natl Cancer Inst 2013; 105 (11) 753-754
    CrossrefPubMedGoogle Scholar
  • 65 Divella R, De Luca R, Abbate I, Naglieri E, Daniele A. Obesity and cancer: the role of adipose tissue and adipo-cytokines-induced chronic inflammation. J Cancer 2016; 7 (15) 2346-2359
    CrossrefPubMedGoogle Scholar
  • 66 Nagle CM, Dixon SC, Jensen A. , et al; Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium. Obesity and survival among women with ovarian cancer: results from the Ovarian Cancer Association Consortium. Br J Cancer 2015; 113 (05) 817-826
    CrossrefPubMedGoogle Scholar
  • 67 Crane TE, Khulpateea BR, Alberts DS, Basen-Engquist K, Thomson CA. Dietary intake and ovarian cancer risk: a systematic review. Cancer Epidemiol Biomarkers Prev 2014; 23 (02) 255-273
    CrossrefPubMedGoogle Scholar
  • 68 Huncharek M, Kupelnick B. Dietary fat intake and risk of epithelial ovarian cancer: a meta-analysis of 6,689 subjects from 8 observational studies. Nutr Cancer 2001; 40 (02) 87-91
    CrossrefPubMedGoogle Scholar
  • 69 Kolahdooz F, Ibiebele TI, van der Pols JC, Webb PM. Dietary patterns and ovarian cancer risk. Am J Clin Nutr 2009; 89 (01) 297-304
    CrossrefPubMedGoogle Scholar
  • 70 Merritt MA, Tzoulaki I, van den Brandt PA. , et al. Nutrient-wide association study of 57 foods/nutrients and epithelial ovarian cancer in the European Prospective Investigation into Cancer and Nutrition study and the Netherlands Cohort Study. Am J Clin Nutr 2016; 103 (01) 161-167
    CrossrefPubMedGoogle Scholar
  • 71 Genkinger JM, Hunter DJ, Spiegelman D. , et al. A pooled analysis of 12 cohort studies of dietary fat, cholesterol and egg intake and ovarian cancer. Cancer Causes Control 2006; 17 (03) 273-285
    CrossrefPubMedGoogle Scholar
  • 72 Hou R, Wu QJ, Gong TT, Jiang L. Dietary fat and fatty acid intake and epithelial ovarian cancer risk: evidence from epidemiological studies. Oncotarget 2015; 6 (40) 43099-43119
    CrossrefPubMedGoogle Scholar
  • 73 Turati F, Galeone C, Gandini S. , et al. High glycemic index and glycemic load are associated with moderately increased cancer risk. Mol Nutr Food Res 2015; 59 (07) 1384-1394
    CrossrefPubMedGoogle Scholar
  • 74 Kolahdooz F, van der Pols JC, Bain CJ. , et al; Australian Cancer Study (Ovarian Cancer) and the Australian Ovarian Cancer Study Group. Meat, fish, and ovarian cancer risk: Results from 2 Australian case-control studies, a systematic review, and meta-analysis. Am J Clin Nutr 2010; 91 (06) 1752-1763
    CrossrefPubMedGoogle Scholar
  • 75 Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. Curr Med Chem 2010; 17 (03) 190-197
    CrossrefPubMedGoogle Scholar
  • 76 Basnet P, Skalko-Basnet N. Curcumin: an anti-inflammatory molecule from a curry spice on the path to cancer treatment. Molecules 2011; 16 (06) 4567-4598
    CrossrefPubMedGoogle Scholar
  • 77 Bishayee A. Cancer prevention and treatment with resveratrol: from rodent studies to clinical trials. Cancer Prev Res (Phila) 2009; 2 (05) 409-418
    CrossrefPubMedGoogle Scholar
  • 78 Quoc Trung L, Espinoza JL, Takami A, Nakao S. Resveratrol induces cell cycle arrest and apoptosis in malignant NK cells via JAK2/STAT3 pathway inhibition. PLoS One 2013; 8 (01) e55183
    CrossrefPubMedGoogle Scholar
  • 79 Amin A, Buratovich M. The anti-cancer charm of flavonoids: a cup-of-tea will do!. Recent Patents Anticancer Drug Discov 2007; 2 (02) 109-117
    CrossrefPubMedGoogle Scholar
  • 80 Chia VM, O'Malley CD, Danese MD. , et al. Prevalence and incidence of comorbidities in elderly women with ovarian cancer. Gynecol Oncol 2013; 129 (02) 346-352
    CrossrefPubMedGoogle Scholar
  • 81 Bakhru A, Buckanovich RJ, Griggs JJ. The impact of diabetes on survival in women with ovarian cancer. Gynecol Oncol 2011; 121 (01) 106-111
    CrossrefPubMedGoogle Scholar
  • 82 Minlikeeva AN, Freudenheim JL, Cannioto RA. , et al; Australian Ovarian Cancer Study Group; Ovarian Cancer Association Consortium. History of hypertension, heart disease, and diabetes and ovarian cancer patient survival: evidence from the ovarian cancer association consortium. Cancer Causes Control 2017; 28 (05) 469-486
    CrossrefPubMedGoogle Scholar
  • 83 Sood AK, Bhatty R, Kamat AA. , et al. Stress hormone-mediated invasion of ovarian cancer cells. Clin Cancer Res 2006; 12 (02) 369-375
    CrossrefPubMedGoogle Scholar
  • 84 Watkins JL, Thaker PH, Nick AM. , et al. Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer. Cancer 2015; 121 (19) 3444-3451
    CrossrefPubMedGoogle Scholar
  • 85 Eskander R, Bessonova L, Chiu C. , et al. Beta blocker use and ovarian cancer survival: a retrospective cohort study. Gynecol Oncol 2012; 127: S21 . Doi: 10.1016/j.ygyno.2012.07.059
    CrossrefPubMedGoogle Scholar
  • 86 Wang SB, Lei KJ, Liu JP, Jia YM. Continuous use of metformin can improve survival in type 2 diabetic patients with ovarian cancer: A retrospective study. Medicine (Baltimore) 2017; 96 (29) e7605
    CrossrefPubMedGoogle Scholar
  • 87 Huo J, Bian XH, Huang Y, Miao ZC, Song LH. Inhibitory effect and mechanism of metformin on human ovarian cancer cells SKOV-3 and A2780. Eur Rev Med Pharmacol Sci 2017; 21 (03) 484-489
    PubMedGoogle Scholar
  • 88 Fu YL, Zhang QH, Wang XW, He H. Antidiabetic drug metformin mitigates ovarian cancer SKOV3 cell growth by triggering G2/M cell cycle arrest and inhibition of m-TOR/PI3K/Akt signaling pathway. Eur Rev Med Pharmacol Sci 2017; 21 (05) 1169-1175
    PubMedGoogle Scholar
  • 89 Shen CJ, Chang CC, Chen YT, Lai CS, Hsu YC. Melatonin suppresses the growth of ovarian cancer cell lines (OVCAR-429 and PA-1) and potentiates the effect of G1 arrest by targeting CDKs. Int J Mol Sci 2016; 17 (02) 176
    CrossrefPubMedGoogle Scholar
  • 90 Li Y, Li S, Zhou Y. , et al. Melatonin for the prevention and treatment of cancer. Oncotarget 2017; 8 (24) 39896-39921
    CrossrefPubMedGoogle Scholar
  • 91 Maruotti N, Cantatore FP. Vitamin D and the immune system. J Rheumatol 2010; 37 (03) 491-495
    CrossrefPubMedGoogle Scholar
  • 92 Lurie G, Matsuno RK, Wilkens LR. , et al. Cataract and ovarian carcinoma: is the vitamin D hypothesis alive?. Cancer Epidemiol Biomarkers Prev 2011; 20 (12) 2507-2511
    CrossrefPubMedGoogle Scholar
  • 93 Ross AC, Manson JE, Abrams SA. , et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab 2011; 96 (01) 53-58
    CrossrefPubMedGoogle Scholar
  • 94 Saunders DE, Christensen C, Wappler NL. , et al. Inhibition of c-myc in breast and ovarian carcinoma cells by 1,25-dihydroxyvitamin D3, retinoic acid and dexamethasone. Anticancer Drugs 1993; 4 (02) 201-208
    CrossrefPubMedGoogle Scholar
  • 95 Merritt MA, Cramer DW, Vitonis AF, Titus LJ, Terry KL. Dairy foods and nutrients in relation to risk of ovarian cancer and major histological subtypes. Int J Cancer 2013; 132 (05) 1114-1124
    CrossrefPubMedGoogle Scholar
  • 96 Lungchukiet P, Sun Y, Kasiappan R. , et al. Suppression of epithelial ovarian cancer invasion into the omentum by 1α,25-dihydroxyvitamin D3 and its receptor. J Steroid Biochem Mol Biol 2015; 148: 138-147
    CrossrefPubMedGoogle Scholar
  • 97 Feldman D, Krishnan AV, Swami S, Giovannucci E, Feldman BJ. The role of vitamin D in reducing cancer risk and progression. Nat Rev Cancer 2014; 14 (05) 342-357
    CrossrefPubMedGoogle Scholar
  • 98 Liu L, Hu Z, Zhang H. , et al. Vitamin D postpones the progression of epithelial ovarian cancer induced by 7, 12-dimethylbenz [a] anthracene both in vitro and in vivo. Onco Targets Ther 2016; 9: 2365-2375
    PubMedGoogle Scholar